H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
- VYNE Therapeutics Ends Phase 2b Trial for Repibresib
- VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
- Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
- Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study